Form 4: Neuronetics Director Receives Equity Grant

Director Sheryl L. Conley was granted 30,000 restricted stock units in Neuronetics, Inc. as part of an equity award.

Summary

• Director Sheryl L. Conley acquired 30,000 restricted stock units (RSUs) on May 28, 2026.
• The RSUs represent a contingent right to receive one share of common stock per unit.
• Following this transaction, the director's total beneficial ownership of common stock is 251,716 shares.
• The award is subject to a vesting schedule tied to service or specific corporate events.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increased total beneficial ownership by the director to 251,716 shares.

Negatives

• None identified in this filing.

Risks

• Vesting is contingent upon continuous service, which could be impacted by future board changes or corporate restructuring.

Future Outlook

The RSU award vests on May 28, 2027, or earlier in the event of a board-approved separation of service or a change in control of the issuer.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.
• The vesting period of one year is typical for annual director equity refresh cycles.

Stakeholder Impact

• Shareholders: Increased alignment of director interests with long-term company performance.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 30,000 RSUs on May 28, 2027, subject to continued service.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Equity Compensation, Director Ownership